“Pharma Wholesale and Distribution market set to grow to $1,447bn by 2025” says new Visiongain report

01 October 2019
Pharma

Visiongain has launched a new pharma report: Pharma Wholesale and Distribution Market Forecasts 2020-2030: Branded Drugs, Generic Drugs, US, China, Japan, Germany, France, Brazil, Italy, Spain, UK, India, Russia, RoW.

The pharmaceutical wholesale and distribution market is influenced by the play of a variety of factors; it has both strengths and weaknesses and faces both opportunities and threats. The market will be driven by an overall increased demand for pharmaceuticals owing to the growing ageing population of developed countries and the increasing access to healthcare of the expanding middle class in the emerging economies.

The lead analyst of the report commented "Over the course of the forecast period, all national pharmaceutical wholesale and distribution markets discussed in this report will experience growth. However, this growth will be significantly faster in emerging markets, such as China. Growth will be faster in these emerging markets as it mirrors growth in the pharmaceutical markets; demand for prescription pharmaceuticals will become much higher in developing countries."

Leading companies featured in the report include Alfresa Holdings, AmerisourceBergen, Cardinal Health, McKesson, Medipal, PHOENIX Group, Shanghai Pharma, SINOPHARM, Suzuken, Walgreens Boots Alliance and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031

Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19.

03 December 2020

Read

Visiongain Publishes Drugs of Abuse Testing Market Report 2021-2031

Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise over the forecast period. The increase in the drugs abuse creates a huge demand for the drugs of abuse testing products.

03 December 2020

Read

Visiongain Publishes Controlled Substance Market Report 2021-2031

Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.

03 December 2020

Read

Visiongain Publishes Companion Animal Diagnostics Market Report 2021-2031

All regions are facing rapid growth in the companion animal population. Companion animal are at high risk of developing various diseases for which companion animal require timely diagnosis for the identification, detection and treatment for life causing diseases.

03 December 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever